Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Impact of Rituximab Maintenance on Survival in Patients with Mantle Cell Lymphoma; a Population-based Cohort Study
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2025018667
document
Newly diagnosed mantle cell lymphoma (MCL) is commonly treated with rituximab (R) combined with anthracycline-based chemotherapy, with or without autologous stem-cell transplantation (ASCT). While rituximab maintenance (RM) in clinical trials has been shown to prolong overall survival (OS), its impact at population level remains largely unknown. This study evaluates the effect of RM on outcome of patients with MCL. Patients aged ≥18 years diagnosed with MCL between 1989-2020 were identified using the Netherlands Cancer Registry, and categorized into periods reflecting R and RM implementation (1989-2000, 2001-2014, 2015-2020). Treatment...
Floriske G Stedema, Mirian Brink, Francien Huisman, Rozemarijn Van Rijn, Aniko Sijs-Szabo, Inger S Nijhof, Arjan Diepstra, Vibeke K J Vergote, Gwendolyn van Gorkom, Thijs W H Flinsenberg, Gerwin A Huls, Tom van Meerten, Jeanette Doorduijn, Wouter J Plattel, Marcel Nijland
A Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T Cells
Published in: Pharmaceutics
Access to document
10.3390/pharmaceutics18040414
document
Background/Objectives: Point-of-care (PoC) manufactured fresh chimeric antigen receptor (CAR)-T cells are typically formulated in hypothermic preservation formulations (HPFs) and stored under hypothermic conditions (2-8 °C) until administered to the patient. However, in current HPFs the shelf life of fresh CAR-T cells is short (~24-36 h) due to limited CAR-T cell stability, which poses significant time constraints on manufacturing procedures and logistics. The objective of this study was to improve the stability and extend the shelf life of fresh clinical-grade CAR-T cell drug products (DPs). Methods: A novel HPF...
Aysenur Öner, Nina Nooteboom, Linette Oosting, Jos G W Kosterink, Bart G J Dekkers, Adrianus C van der Graaf, Tom van Meerten, Guido Krenning, Daniel H Swart, Robin Dennebos, Harm-Jan Lourens, Edwin Bremer, Bahez Gareb
Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Published in: Nature Communications
Access to document
10.1038/s41467-026-69473-2
document
Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum, Nienke A M Smit, Adrienne H Brouwers, Joyce van Sluis, Marjolijn N Lub-de Hooge, Frank R Pierik, Gerwin A Huls, Lisanne V van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P Williams, Alexander Ungewickell, Sjoerd G Elias, Elisabeth G E de Vries, Anne G H Niezink, Tom van Meerten
Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia
Published in: Journal of translational medicine
Access to document
10.1186/s12967-026-07701-5
document
Background: Chimeric Antigen Receptor (CAR)-T cell therapy holds considerable promise for the treatment of CD7+ T cell malignancies. However, a major challenge limiting clinical development of CD7-targeted CARs has been fratricide,a process of self-cytotoxicity caused by the shared expression of CD7 on malignant and healthy cells. Current solutions, including CD7 gene editing, intracellular retention or cell-sorting strategies, add significant complexity and cost, thereby limiting the feasibility and cost-effectiveness of this therapy. In this study, we evaluated whether fratricide can instead be overcome by tailoring standard manufacturing protocols to...
Jimena Álvarez Freile, Lena Rockstein, Rianne Kloosterman, Macarena González Corrales, Nienke Visser, Harm Jan Lourens, Orsolya Frittmann, Robin Dennebos, Nienke A M Smit, Airies Setroikomo, Marta Requesens, Nienke van Rooij, Aysenur Öner, Marco de Bruyn, Tom van Meerten, Mar Bellido, Gerwin Huls, Bahez Gareb, Edwin Bremer
Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-025-07340-w
document